JP2020532555A - ダントロレンを使用して神経薬暴露を治療する方法 - Google Patents

ダントロレンを使用して神経薬暴露を治療する方法 Download PDF

Info

Publication number
JP2020532555A
JP2020532555A JP2020512813A JP2020512813A JP2020532555A JP 2020532555 A JP2020532555 A JP 2020532555A JP 2020512813 A JP2020512813 A JP 2020512813A JP 2020512813 A JP2020512813 A JP 2020512813A JP 2020532555 A JP2020532555 A JP 2020532555A
Authority
JP
Japan
Prior art keywords
dantrolene
subject
pharmaceutical composition
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020512813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532555A5 (https=
Inventor
ヘプナー、エイドリアン
Original Assignee
イーグル ファーマスーティカルズ、インク．
イーグル ファーマスーティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーグル ファーマスーティカルズ、インク．, イーグル ファーマスーティカルズ、インク． filed Critical イーグル ファーマスーティカルズ、インク．
Publication of JP2020532555A publication Critical patent/JP2020532555A/ja
Publication of JP2020532555A5 publication Critical patent/JP2020532555A5/ja
Priority to JP2023010846A priority Critical patent/JP2023055802A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020512813A 2017-09-05 2018-09-05 ダントロレンを使用して神経薬暴露を治療する方法 Pending JP2020532555A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023010846A JP2023055802A (ja) 2017-09-05 2023-01-27 ダントロレンを使用して神経薬暴露を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554049P 2017-09-05 2017-09-05
US62/554,049 2017-09-05
US201862674406P 2018-05-21 2018-05-21
US62/674,406 2018-05-21
PCT/US2018/049515 WO2019050923A1 (en) 2017-09-05 2018-09-05 METHODS OF USING DANTROLENE TO TREAT EXPOSURE TO A NEUROTOXIC AGENT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023010846A Division JP2023055802A (ja) 2017-09-05 2023-01-27 ダントロレンを使用して神経薬暴露を治療する方法

Publications (2)

Publication Number Publication Date
JP2020532555A true JP2020532555A (ja) 2020-11-12
JP2020532555A5 JP2020532555A5 (https=) 2021-07-26

Family

ID=63708449

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512813A Pending JP2020532555A (ja) 2017-09-05 2018-09-05 ダントロレンを使用して神経薬暴露を治療する方法
JP2023010846A Pending JP2023055802A (ja) 2017-09-05 2023-01-27 ダントロレンを使用して神経薬暴露を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023010846A Pending JP2023055802A (ja) 2017-09-05 2023-01-27 ダントロレンを使用して神経薬暴露を治療する方法

Country Status (15)

Country Link
US (2) US20200383954A1 (https=)
EP (1) EP3678659B1 (https=)
JP (2) JP2020532555A (https=)
KR (1) KR20200047655A (https=)
CN (1) CN111093652A (https=)
AU (1) AU2018328131B2 (https=)
BR (1) BR112020004429A2 (https=)
CA (1) CA3074732A1 (https=)
IL (1) IL272847B1 (https=)
MA (1) MA50080A (https=)
MX (2) MX2020002485A (https=)
SG (1) SG11202001749SA (https=)
UA (1) UA126688C2 (https=)
WO (1) WO2019050923A1 (https=)
ZA (1) ZA202001258B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538608A (ja) * 2019-06-28 2022-09-05 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア アルツハイマー病の治療のための鼻腔内ダントロレン投与
WO2023081873A1 (en) * 2021-11-05 2023-05-11 Quorum Innovations, Llc Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525439A (ja) * 2003-03-04 2007-09-06 リオトロピック セラピュティックス アイエヌシー． ダントロレンを用いる治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2013040501A1 (en) * 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525439A (ja) * 2003-03-04 2007-09-06 リオトロピック セラピュティックス アイエヌシー． ダントロレンを用いる治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCH. TOXICOL., vol. 73, JPN6022009413, 1999, pages 473 - 478, ISSN: 0004888090 *
DTIC TECHNICAL REP., JPN6022009410, 2003, pages 443565, ISSN: 0004888087 *
MEDICAL ASPECTS OF CHEMICAL WARFARE CHAPTER 6, JPN6022009412, 2008, pages 221 - 242, ISSN: 0004888089 *
NEUROLOGY, vol. Vol.60 No.5 Suppl 1, JPN6022009411, 2003, pages 385, ISSN: 0004888088 *

Also Published As

Publication number Publication date
JP2023055802A (ja) 2023-04-18
EP3678659C0 (en) 2025-12-17
MX2020002485A (es) 2020-07-20
SG11202001749SA (en) 2020-03-30
BR112020004429A2 (pt) 2020-10-20
RU2020112318A (ru) 2021-10-06
NZ762056A (en) 2025-10-31
AU2018328131B2 (en) 2024-04-18
US20200383954A1 (en) 2020-12-10
EP3678659A1 (en) 2020-07-15
UA126688C2 (uk) 2023-01-11
MA50080A (fr) 2020-07-15
IL272847B1 (en) 2026-03-01
MX2023012415A (es) 2023-11-01
CA3074732A1 (en) 2019-03-14
US20220087980A1 (en) 2022-03-24
AU2018328131A1 (en) 2020-03-12
ZA202001258B (en) 2023-10-25
RU2020112318A3 (https=) 2021-10-26
EP3678659B1 (en) 2025-12-17
CN111093652A (zh) 2020-05-01
IL272847A (en) 2020-04-30
WO2019050923A1 (en) 2019-03-14
KR20200047655A (ko) 2020-05-07

Similar Documents

Publication Publication Date Title
Leibson et al. Organophosphate and carbamate poisoning: review of the current literature and summary of clinical and laboratory experience in southern Israel
Dickson et al. Diazepam inhibits organophosphate‐induced central respiratory depression
CN102657664A (zh) 用于治疗疼痛和其它α2肾上腺素能介导疾病的方法及组合物
BG65795B1 (bg) Приложение на ретигабин за лечение на невропатична болка
EP2958624B1 (en) Treatment of graft versus host disease in transplant patients
Dorandeu et al. Efficacy of the ketamine–atropine combination in the delayed treatment of soman-induced status epilepticus
KR20230173743A (ko) 트라디피턴트에 의한 치료 방법
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JP2023055802A (ja) ダントロレンを使用して神経薬暴露を治療する方法
Anderson et al. Antagonism of soman-induced convulsions by midazolam, diazepam and scopolamine
US20110144093A1 (en) Method of treating organophosphorous poisoning
JP7269875B2 (ja) ピラゾロキノリン誘導体を含有するレビー小体病治療剤
US20240366565A1 (en) Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
Thomas et al. In vivo evaluation of a1 adenosine agonists as novel anticonvulsant medical countermeasures to nerve agent intoxication in a rat soman seizure model
Skovira et al. Neuropharmacological specificity of brain structures involved in soman-induced seizures
EA036347B1 (ru) Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы
EP0414568A2 (en) Use of anticholinergic compounds for protecting the central nervous system against cholinergic neurotoxins
Oh et al. Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation
Huang et al. Effect of praziquantel prolonged administration on granuloma formation around Schistosoma japonicum eggs in lung of sensitized mice
RU2817851C2 (ru) Способы применения дантролена для лечения воздействия нервно-паралитического вещества
Guarnieri et al. Subcutaneous Implants of a Cholesterol‐Triglyceride‐Buprenorphine Suspension in Rats
Winkler et al. Anticonvulsant efficacy of antihistamine cyproheptadine in rats exposed to the chemical warfare nerve agent soman
KR20190008225A (ko) 화학적 신경차단으로 인한 부작용의 치료
EP3429563B1 (en) Desformylflustrabromine for use in the treatment of obsessive-compulsive and related disorders
Thomas et al. Pharmacological Evaluation of Candidate Adenosine Agonists as Novel Anticonvulsant Medical Countermeasures to Soman Nerve Agent Intoxication

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221004